Larisa Rudenko is at the Program on Emerging Technologies at the Massachusetts Institute of Technology where she studies the governance of emerging biotechnologies focusing on science- and values-based concerns. The technical areas on which she concentrates include genome editing, gene drives, biosecurity, and novel foods, including cell cultured meat. Prior to her appointment at MIT, she spent 15 years at the Food and Drug Administration, developing and implementing the agency’s policy for the regulation of the products of animal biotechnology, including primary authorship of the animal cloning risk assessment, and overseeing the first FDA approvals for genetically engineered animals including the world’s first approval of food from a genetically engineered animal. Prior to her government service, she worked in the consultancy and for VC to perform due diligence on various products and processes, as well as developing risk/safety assessments for products from microorganisms through complex mammals. Dr. Rudenko is internationally recognized for successful leadership and collegial collaboration in developing coordinated strategies and harmonized consensus documents. She serves on science and technology advisory boards for the products of emerging biotechnologies, including alternative sources of protein and cellular agriculture, and sits on several domestic and international grant reviews. Dr. Rudenko is a frequent invited speaker on governance and regulatory issues, public perception, and on the status of emerging biotechnologies, including podcasts and various media interviews. She has frequently addressed National Academies of Science, Engineering, and Medicine working groups, and the NIH NExTRAC on issues associated with governance and regulation of emerging biotechnologies. As a founder of BioPolicy Solutions, LLC, she assists investors with due diligence reviews in the emerging biotechnology space, and assists companies in planning product development and regulatory strategies. She received her PhD in Cellular and Molecular Pharmacology from Stony Brook University after completing her doctoral work in DNA damage and repair at the Brookhaven National Laboratory; she is a Diplomate of the American Board of Toxicology.